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Plasminogen Activators, Matrix Metalloproteinases,
and Their Inhibitors in Implanted Vascular Prostheses
H. Urayama∗, S. Katada, F. Kasashima, Y. Tanaka, K. Kawasuji and Y. Watanabe
First Department of Surgery, Kanazawa University School of Medicine, Kanazawa, Japan
Objectives: to examine the role of plasminogen activators (PAs) and matrix metalloproteinases (MMPs) in the healing
of prosthetic grafts.
Methods: thirty explanted grafts (16 Dacron and 14 PTFE) were studied immunohistochemically using antibodies to
PAs, MMPs, and their inhibitors. The percentages of immunostain-positive multinucleated giant cells (MGC) were
related to duration of implantation (early vs late), type of lesion (stenosis vs false aneurysm), graft material (Dacron vs
PTFE), and graft status (occluded vs patent).
Results: all specimens were positive for PAs and MMPs. There were no significant differences in the percentages of
MGCs positive for PAs, MMPs, or tissue inhibitor type 2 of MMP (TIMP-2) between the groups. The percentage of
TIMP-1 in the aneurysm group (mean, 26%) was significantly lower than that of the stenosis group (mean, 46%)
(p<0.05).
Conclusion: after the implantation of a vascular prosthesis, PAs and MMPs are expressed in cell migration, proliferation
and matrix construction. Under-expression of TIMP-1 may be related to the formation of an anastomotic aneurysm.
Key Words: Vascular prosthesis; Intimal hyperplasia; Anastomotic aneurysm; Matrix metalloproteinase; Plasminogen
activator.
Introduction create a barrier-like structure,12 and the immunological
reaction to the foreign body is controlled and stabilised
Direct vascular anastomosis elicits acute inflammation in most implanted grafts.4 Loss of such control may
result in excessive intimal hyperplasia or anastomoticand then heals completely.1–3 In implanted prostheses,
however, acute inflammation is followed by an aneurysm.
The aim of this study was to examine the expressionimmunological reaction to the foreign body.4 Throm-
bosis occurs in direct sutures at the anastomotic site of PAs, MMPs, and their inhibitors by MGCs in the
anastomotic region of explanted prosthetic grafts.and is replaced by re-endothelialisation. However, the
luminal surface of the implanted prosthesis is not
covered with endothelium except at the anastomotic
site.2
As a result of incomplete healing prosthetic grafts Materials and Methods
are prone to occlusion by stenosis and anastomotic
aneurysm formation.5,6 Thirty vascular prostheses were retrieved at operation
Plasminogen activators (PAs) and matrix metal- or autopsy. Seven Dacron grafts had been implanted
loproteinases (MMPs) play a role in intimal hy- for aortic aneurysm, and nine for arteriosclerotic oc-
perplasia, plaque rupture, and wall dilatation.7–10 In clusive disease. Fourteen PTFE grafts had been im-
wound healing, PAs and MMPs degrade damaged planted for occlusive disease. Implanted grafts were
tissues and play a role in cell migration.11 In the healing obtained at revision surgery from four patients with
process of implanted prostheses, multinucleated giant anastomotic stenosis (implantation periods were 8, 54,
cells (MGCs) surround the prosthetic material. MGCs 111, and 166 months), and from four patients with
anastomotic aneurysms (implantation periods were
28, 54, 97 and 139 months). The observation periods
∗ Please address all correspondence to: H. Urayama, First De- ranged from 5 days to 166 months (median, 52 months).partment of Surgery, Kanazawa University School of Medicine, 13-1,
Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. For autopsy specimens, the delay between death
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U.S.A.); -actin (cells identified; smooth muscle cell)
(DAKO); macrophages (DAKO), von Willebrand factor
(endothelial cell) (DAKO); CD3 (T cell) (DAKO), and
CD20 (B cell) (DAKO). MMP types 1 (collagenase),
MMP-2 (gelatinase-A), MMP-3 (stromelysin-1), MMP-
7 (matrilysin), MMP-9 (gelatinase-B); tissue inhibitor
Fig. 1. Immunostaining for MMP-1 (A), u-PA (B), and u-PAR (C) in a PTFE graft 21 days after implantation. Macrophages and fibroblasts,
which migrated from the outside of the graft, are positive for MMP-1 and u-PA; some are also positive for u-PAR. Immunostaining for
t-PA at the anastomotic region (D) and on the luminal surface (E), and PAI-1 (F) in a Dacron graft 22 months after implantation. Endothelial
cells and smooth muscle cells at the anastomotic region are positive for t-PA. Macrophages and the fibrin layer are positive for t-PA, but
only a few macrophages are positive for PAI-1 on the luminal surface of the graft. The bar represents 20 m.
and graft retrieval was always less than 60 min.
Samples were immersion-fixed in 10% neutral buffered
formalin and then embedded in paraffin. Sections
were stained with haematoxylin and eosin, azan, and
Verhoeff–van Gieson stains. Serial sections were in-
cubated with monoclonal antibodies2 (source; DAKO
Japan, Tokyo, Japan); elastin (Sigma, St. Louis, Mo., type 1 of MMPs (TIMP-1), TIMP-2, tissue type PA (t-
PA), urokinase type PA (u-PA), u-PA receptor (u-PAR),U.S.A.); collagen types I to V (SBA, Birmingham, Ala.,
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Fig. 2. Multinucleated giant cells are positive for MMPs and TIMPs. Immunostaining for MMP-3 (a), MMP-7 (b), and TIMP-2 (c) in a
Dacron graft at 57 days after implantation. (d), immunostaining for MMP-2 in a Dacron graft 12 months after implantation. (e),
immunostaining for MMP-9 in a PTFE graft 41 months after implantation. (f), immunostaining for TIMP-1 in a Dacron graft 148 months
after implantation. Immunostaining for MMP-2 (g) and for MMP-9 (h) in a Dacron graft with an anastomotic aneurysm 54 months after
implantation. MGCs are stained for MMP-2 and -9, and fibroblasts are stained for MMP-2. The bar represents 20 m.
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and PA inhibitor type 1 (PAI-1). The antibodies against u-PA, u-PAR, and MMP-2. No B cells were detected.
Some macrophages and fibroblasts in surroundingMMPs and TIMPs were provided by the Department
of Virology, Cancer Research Institute, Kanazawa Uni- tissues and between the graft fibres were positive for
t-PA, u-PA, u-PAR, MMP-1, MMP-9, and TIMP-2. T-versity.13 The antibodies against PAs, u-PAR, and PAI-
1 were obtained from American Diagnostica, Inc. PA, u-PA, PAI-1, MMP-1, -2, -3, -7, -9, and TIMP-1
and -2 were present in the MGCs surrounding the(Greenwich, Ct., U.S.A.). Avidin-biotin immuno-
peroxidase was used for immunolabelling.2 grafts.
In samples of anastomotic hyperplasia, some smoothThe percentage of positively staining MGCs was
calculated. These data were related to duration of muscle cells were positive for t-PA, u-PA, MMP-1,
-3, -7, -9, and TIMP-2. In the fibrin layer of anastomoticimplantation; graft material (Dacron vs PTFE), graft
status (occluded vs patent), and type of lesion (stenosis stenosis, some macrophages were positive for t-PA, u-
PA, u-PAR, and MMP-1, -2, -3, and -9. In samplesvs false aneurysm). The data are presented as
means±SD and analysed using the Student’s t-test. of anastomotic aneurysm, t-PA, u-PA, u-PAR, PAI-1,
MMP-1, -2, -3, -7, -9, TIMP-1, and -2 were present inSignificance was defined as p<0.05.
MGCs surrounding the graft fibres and sutures. The
immunostaining for PAI-1 was weak in the MGCs
(Figs 1, 2).
Results The mean values of immunostained MGCs at ana-
stomotic regions were 86% for t-PA, 84% for u-PA,
Macrophages in anastomotic thrombi stained for t-PA, 81% for u-PAR, 72% for PAI-1, 88% for MMP-1, 82%
u-PA, u-PAR, PAI-1, MMP-1, -2, -3, -9, and TIMP-1 for MMP-2, 51% for MMP-3, 78% for MMP-7, 83% for
and -2. The immunostaining for PAI-1, TIMP-1, and MMP-9, 45% for TIMP-1, and 59% for TIMP-2. There
TIMP-2 was weak in the macrophages. In the mid- were no significant differences in PAs, u-PAR, PAI-1,
portion of the PTFE graft 21 days after implantation, MMPs, or TIMP-2 between early retrieal vs late re-
fibroblasts had migrated from the outside to the lu- trieval, stenosis vs false aneurysm, Dacrons vs PTFEs,
minal surface and were positive for t-PA, u-PA, u- or occluded grafts vs patent grafts. The percentage
PAR, MMP-1, and MMP-2. At the anastomotic site, of TIMP-1 in the aneurysm group (mean, 26%) was
the smooth muscle cells had migrated from the host significantly lower than that in the stenosis group
artery to the luminal surface of the graft and were (mean, 46%) (p<0.05) (Tables 1, 2).
positive for t-PA, u-PA, u-PAR, MMP-1, and MMP-2.
MGCs were found around the graft and stained for t-
PA, u-PA, u-PAR, PAI-1, MMP-1, -2, -3, -7, -9, and
TIMP-1 and -2. The immunostaining for PAI-1, TIMP- Discussion
1, and TIMP-2 was weak in MGCs. The endothelial
cells in the anastomosis of the Dacron graft 24 days In the healing of implanted vascular prostheses, PAs
and MMPs are expressed during cell migration andafter implantation were immunostained for t-PA, u-
PA, and MMP-1, -2, -3 and -9. matrix remodelling. Thrombi are formed on the lu-
minal surface of the graft, and monocytes/macro-At later times, connective tissues were formed at
the anastomosis and at some parts of the luminal phages migrate into the thrombi to remove them.2
Smooth muscle cells or fibroblasts migrate from thesurface of the grafts. Most of the collagen in the
connective tissue was type III, and some type I collagen host artery or surrounding tissues into the luminal
surface of the graft and produce collagen and otherwas present with collagen type III. Type IV collagen
was detected around the smooth muscle cells at the matrix components.
MGCs cluster around the graft fibres and expressanastomosis and around the fibroblasts in the mid-
portion of the grafts. In most parts of the connective PAs and MMPs as in wound healing.1 Neo-
vascularisation in the connective tissues around thetissue on the luminal surfaces, the smooth muscle cells,
fibroblasts, and macrophages were not stained for graft is also regulated by PAs and MMPs.14
In the late phase of graft healing, a thin layer ofMMPs, but some were stained for t-PA and u-PA. T-
PA was also detected in the endothelial cells at the fibrin and collagen covers the luminal surface and
gains anti-thrombotic properties.15 The MGCs sur-anastomosis and in the connective tissues and fibrin
layers on the luminal surface of the graft. The endo- rounding the graft fibres express PAs and MMPs,
degrading the connective tissues to allow the passagethelial cells in the small vessels around the grafts were
positive for t-PA, u-PA, and MMP-1, -2, -3, and -9. of cells into the graft and luminal surface. The migrated
macrophages become phagocytes in the fibrin, and theSome T cells in the perigraft tissues were positive for
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migrated fibroblasts produce collagen.16 Neo- Acknowledgements
vascularisation into the graft sprouts new capillaries.
This study was supported by Grant-in-Aid (No. 08671346) forThus, the MGCs surrounding the graft act not as a
Scientific Research from the Ministry of Education, Science, Sports
barrier, but as a modulator for continuous remodelling and Culture, Japan.
of the connective tissues, in which the production
of extracellular matrix is correlated to the extent of
proteolysis. The endothelial cells at the anastomotic References
site and fibroblasts at other parts of the graft express
1 Martin P. Wound healing: aiming for perfect skin regeneration.PAs, contributing to the anti-thrombogenesis of the
Science 1997; 276: 75–81.luminal surface.17 2 Urayama H, Kasashima F, Kawakami T, Kawakami K, Wa-
tanabe Y. An immunohistological analysis of implanted wovenThe grafts implanted for aneurysmal disease did not
Dacron and expanted polytetrafluoroethylene grafts in humans.differ from those implanted in patients for occlusive
Artif Organs 1996; 20: 24–29.
disease. Nor was there any difference between Dacron 3 Khodadad G. Histological evaluation of long-term micro-
vascular repair and replacement. Arch Surg 1970; 101: 503–507.and PTFE,2 or between occluded and patent grafts.
4 Greisler HP, Kim DU, Price JB, Voorhees AB Jr. ArterialThe percentages of MGCs immunostained for PAs
regenerative activity after prosthetic implantation. Arch Surg
and MMPs in the grafts with anastomotic stenosis did 1985; 120: 315–323.
5 Chervu A, Moore WS. An overview of intimal hyperplasia.not differ from those in the grafts without stenosis. In
Surg Gynecol Obstet 1990; 171: 433–447.spite of activated MGCs, smooth muscle cells and 6 Mii S, Sakata H, Kawazoe N. Para-anastomotic aneurysms:
macrophages at the anastomotic site were inactive in incidence, risk factors, treatment and prognosis. J Cardiovasc Surg
1998; 39: 259–266.the late phase, and our results confirmed that normal
7 Raghunath PN, Tomaszewski JE, Brady ST et al. Plasminogenhealing of the graft does not cause excessive intimal activator system in human coronary atherosclerosis. Arterioscler
hyperplasia.4 However, deleterious events such as Thromb Vasc Biol 1995; 15: 1432–1443.
8 Lupu F, Heim DA, Bachmann F et al. Plasminogen activatorthrombosis or mechanical stress may cause migration
expression in human atherosclerotic lesions. Arterioscler Thromband proliferation of smooth muscle cells, fibro- Vasc Biol 1995; 15: 1444–1455.
blasts, and macrophages, resulting in anastomotic 9 Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression
of matrix metalloproteinases and matrix degrading activity instenosis.19,20
vulnerable regions of human atherosclerotic plaques. J Clin Invest
In an atherosclerotic aneurysm, MMPs in smooth 1994; 94: 2493–2503.
10 McMillan WD, Patterson BK, Keen RR et al. In situ localizationmuscle cells and macrophages are upregulated and
and quantification of mRNA for 92-kD Type IV collagenasedegrade elastin and collagen.21 In the anastomotic
and its inhibitor in aneurysmal, occlusive, and normal aorta.
aneurysms, the expression of MMPs was not increased Arterioscler Thromb Vasc Biol 1995; 15: 1139–1144.
11 Woessner JF Jr. Matrix metalloproteinases and their inhibitorsin smooth muscle cells, macrophages, or MGCs at the
in connective tissue remodeling. FASEB J 1991; 5: 2145–2154.anastomosis, but expression of TIMP-1 was decreased 12 Smetana K Jr. Multinucleate foreign-body giant cell formation.
in MGCs. This suggests that in an anastomotic an- Exp Mol Pathol 1987; 46: 258–265.
13 Okada Y, Naka Y, Kawamura K et al. Localization of matrixeurysm the continuous remodelling of connective tis-
metalloproteinase 9 (92-kilodalton gelatinase/type IV col-sues may deviate from balanced reconstruction to lagenase=gelatinase B) in osteoclasts: implications for bone
degradation, and some mechanisms other than those resorption. Lab Invest 1995; 72: 311–322.
14 Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrixin the atherosclerotic aneurysm may have caused the
metalloproteinases regulate neovascularization by acting as per-deviation. This difference in percentage of TIMP-1 icellular fibrinolysins. Cell 1998; 95: 365–377.
between the aneurysm and the stenosis group should, 15 Stratton JR, Thiele BL, Ritchie JL. Natural history of platelet
deposition on Dacron aortic bifurcation grafts in the first yearhowever, be interpreted cautiously, as it could be a
after implantation. Am J Cardiol 1983; 52: 371–374.result of multiple comparisons. 16 Shibuya T, Kambayashi J, Okahara K et al. Subendothelial
layer of pseudointima of polytetrafluoroethylene graft is formedIn this study, we found that PAs and MMPs are
by transformation of fibroblasts migrated from extravascularexpressed in cell migration and proliferation and in
space. Eur J Vasc Surg 1994; 8: 276–285.
matrix remodeling after the implantation of a vascular 17 Chang R, Powell RJ, Sumpio BE. Tissue plasminogen activator:
biologic perspective for surgeons. J Am Coll Surgeons 1997; 184:prosthesis. The most outstanding finding was the great
529–539.activity of MGCs surrounding the graft. They play an 18 Okada Y. Light and electron microscopic study on the or-
important role in the continuous remodeling of the ganization of occlusive thrombus. J Juzen Med Soc 1982; 91:
967–980.connective tissues as the graft heals. As a therapeutic
19 Bassiouny HS, White S, Glagov S et al. Anastomotic intimalapproach for small anastomotic aneurysms, TIMP-1 hyperplasia: mechanical injury or flow induced. J Vasc Surg 1992;
may be increased through gene delivery.22 When new 15: 708–717.
20 Clowes AW, Kirkman TR, Clowes MM. Mechanism of arterialvascular prostheses are developed, the immunological
graft failure-II: chronic endothelial and smooth muscle cell pro-reaction to a foreign body may be regulated to target liferation in healing polytetrafluoroethylene prostheses. J Vasc
Surg 1986; 3: 877–884.MGCs.
Eur J Vasc Endovasc Surg Vol 20, December 2000
PA and MMP in Vascular Prostheses 507
21 Freestone T, Turner RJ, Coady A, Higman DJ et al. In- Local overexpression of TIMP-1 prevents aortic aneurysm de-
generation and rupture in a rat model. J Clin Invest 1998; 102:flammation and matrix metalloproteinases in the enlarging ab-
1413–1420.dominal aortic aneurysm. Arteroscler Thromb Vasc Biol 1995; 15:
1145–1151.
22 Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Accepted 29 September 2000
Eur J Vasc Endovasc Surg Vol 20, December 2000
